Bedger and all,
J&J or other big pharma ATI licensing would be significant and a study (assume 2nd phase) clearance in the US by the FDA would be considered in my personal view an important pre-requisite for J&J to extend on the exisiting collaboration. Having said that, there could be mid-size companies with focus on autologous stem cells and an already proven footprint in this area who could offer significant partnership opportunity to accelerate pathway and ultimately market adoption of OCC autologous stem cell range. One of these companies is Vericel, a leading US autologous stem cell company. The following is taken from their most recent presentation which I thought I'd share.
As always, do your own research. This is purely a speculative thought based on potential strategic fit.![]()
- Forums
- ASX - By Stock
- OCC
- Ann: Investor Presentation
Ann: Investor Presentation, page-41
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
|
|||||
Last
46.0¢ |
Change
0.020(4.55%) |
Mkt cap ! $96.40M |
Open | High | Low | Value | Volume |
44.0¢ | 46.5¢ | 44.0¢ | $242.2K | 539.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 47961 | 46.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
47.0¢ | 18951 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 47961 | 0.460 |
1 | 32867 | 0.455 |
1 | 2200 | 0.445 |
3 | 95682 | 0.440 |
1 | 10005 | 0.430 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 18951 | 3 |
0.480 | 73269 | 4 |
0.485 | 52000 | 1 |
0.490 | 105080 | 2 |
0.495 | 5288 | 2 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |